Why the Race Oncology (ASX:RAC) share price surged 7% today

Race Oncology shares shot out of the starting blocks today after positive study results.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Race Oncology Ltd (ASX: RAC) share price jumped out of the starting blocks today, shooting up 7% to a high of $3.66. This was after the biopharma company announced a key update on results from one of its research programs.

The Race Oncology share price has since lost some ground, however, and is currently trading at $3.46, still 2.37% higher than yesterday's closing price.

Here's what we know.

Positive melanoma study results

Race Oncology advised today that its anti-cancer drug label, Zantrene, was shown to be effective in destroying highly active skin cancer cells in mice.  

This followed promising results from its "collaborative preclinical melanoma research program" with the University of Newcastle.

The company said the program involved researchers exploring Zantrene's effectiveness as a novel treatment for the malignant type of skin cancer known as melanoma.

Interim results demonstrated Zantrene to be "highly effective at killing a diverse range of high FTO producing melanoma cell subtypes".

This means is that Zantrene is showing early signs of potentially becoming a treatment for melanoma.

However, there is still a whole wave of evidence to produce, and a mountain of regulatory headwinds to overcome before that becomes reality.

Nonetheless, key takeouts from the study include that Zantrene is "highly effective in killing melanoma cells at sub-chemotherapeutic levels", and that it achieved these results at low concentrations.

Race Oncology believes the results were "highly supportive" of future clinical trials to investigate Zantrene's use as a combination therapy in melanoma treatment.

Management commentary

Speaking on the announcement, Race Oncology CEO Phillip Lynch said the company was encouraged by its work so far:

While challenged by COVID-19 related shutdowns, we appreciate the encouraging and continued work from the team at the University of Newcastle.

Zantrene continues to positively surprise us – we are very pleased with these early results. Melanoma remains a difficult cancer to treat, and one that's of particular relevance to the Australian community, so as we continue with this work, we look forward to learning more about our potential to offer new treatment options to patients.

Race Oncology share price snapshot

The Race Oncology share price has climbed 97% year to date and rallied 12.7% in the past month.

Over the past 12 months, Race Oncology shareholders have enjoyed a return of 339.4%, well ahead of the S&P/ASX 200 index (ASX: XJO)'s gain of about 25% in this time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »